O	0	1	A
O	2	12	randomised
O	13	23	controlled
O	24	29	trial
O	30	32	of
B-intervention	33	40	support
I-intervention	41	46	group
I-intervention	47	59	intervention
O	60	65	after
O	66	72	breast
O	73	79	cancer
O	80	89	treatment
O	89	90	:
O	91	98	results
O	99	101	on
B-condition	102	109	anxiety
I-condition	110	113	and
I-condition	114	124	depression
O	124	125	.

O	126	134	Previous
O	135	142	studies
O	143	147	have
O	148	160	demonstrated
O	161	165	that
O	166	173	between
O	174	176	20
O	177	180	and
O	181	183	30
O	183	184	%
O	185	187	of
O	188	193	women
O	194	201	treated
O	202	205	for
O	206	212	breast
O	213	219	cancer
O	220	224	have
O	225	235	measurable
O	236	241	signs
O	242	244	of
O	245	252	anxiety
O	253	256	and
O	257	267	depression
O	268	276	compared
O	277	281	with
O	282	283	6
O	283	284	%
O	285	287	in
O	288	289	a
O	290	300	population
O	301	303	of
O	304	311	healthy
O	312	317	women
O	317	318	.

O	319	329	Depression
O	330	333	has
O	334	338	been
O	339	347	proposed
O	348	350	as
O	351	352	a
O	353	363	predictive
O	364	370	factor
O	371	374	for
O	375	385	recurrence
O	386	389	and
O	390	398	survival
O	398	399	.

O	400	403	The
O	404	407	aim
O	408	410	of
O	411	414	the
O	415	422	present
O	423	428	study
O	429	432	was
O	433	435	to
O	436	444	evaluate
O	445	447	if
O	448	460	psychosocial
O	461	468	support
O	469	481	intervention
O	482	487	could
O	488	497	influence
O	498	505	anxiety
O	506	509	and
O	510	520	depression
O	521	527	during
O	528	531	the
O	532	537	first
O	538	542	year
O	543	548	after
O	549	558	diagnosis
O	558	559	.

B-eligibility	560	565	Newly
I-eligibility	566	575	diagnosed
I-eligibility	576	582	breast
I-eligibility	583	589	cancer
I-eligibility	590	598	patients
O	599	603	were
O	604	614	randomised
O	615	622	between
O	623	628	April
O	629	633	2002
O	634	637	and
O	638	646	November
O	647	651	2007
O	652	655	and
O	656	666	stratified
O	667	669	by
O	670	678	adjuvant
O	679	691	chemotherapy
O	691	692	.

O	693	695	Of
B-total-participants	696	699	382
O	700	708	eligible
O	709	717	patients
O	717	718	,
B-intervention-participants	719	722	191
O	723	724	+
B-control-participants	725	728	191
O	729	737	patients
O	738	742	were
O	743	753	randomised
O	754	756	to
O	757	769	intervention
O	770	775	group
O	776	778	or
B-control	779	786	control
I-control	787	792	group
O	792	793	,
O	794	806	respectively
O	806	807	.

O	808	815	Control
O	816	824	patients
O	825	829	were
O	830	839	subjected
O	840	842	to
B-control	843	851	standard
I-control	852	858	follow
I-control	858	859	-
I-control	859	861	up
I-control	862	870	routines
O	870	871	.

O	872	875	The
O	876	888	Intervention
O	889	894	group
O	895	898	had
O	899	906	support
O	907	919	intervention
O	920	922	at
O	923	926	the
O	927	937	Foundation
O	938	943	Lustg
O	943	944	å
O	944	948	rden
O	949	950	M
O	950	951	ä
O	951	959	lardalen
O	959	960	.

O	961	964	The
O	965	979	rehabilitation
O	980	986	lasted
O	987	990	one
O	991	995	week
O	996	998	on
O	999	1000	a
O	1001	1012	residential
O	1013	1018	basis
O	1019	1027	followed
O	1028	1030	by
O	1031	1035	four
O	1036	1040	days
O	1041	1043	of
O	1044	1050	follow
O	1050	1051	-
O	1051	1053	up
O	1054	1057	two
O	1058	1064	months
O	1065	1070	later
O	1070	1071	.

O	1072	1074	We
O	1075	1079	used
O	1080	1083	the
O	1084	1091	Swedish
O	1092	1099	version
O	1100	1102	of
O	1103	1106	the
O	1107	1110	HAD
O	1111	1116	scale
O	1117	1121	with
O	1122	1123	a
O	1124	1127	cut
O	1127	1128	-
O	1128	1131	off
O	1132	1137	value
O	1138	1145	greater
O	1146	1150	than
O	1151	1153	10
O	1154	1157	for
B-outcome	1158	1166	clinical
I-outcome	1167	1175	symptoms
I-outcome	1176	1178	of
I-outcome	1179	1189	depression
I-outcome	1190	1193	and
I-outcome	1194	1201	anxiety
O	1201	1202	.

O	1203	1210	Support
O	1211	1216	group
O	1217	1229	intervention
O	1230	1237	lowered
B-outcome	1238	1245	anxiety
I-outcome	1246	1250	over
I-outcome	1251	1255	time
O	1256	1257	(
O	1257	1258	p
O	1259	1260	<
O	1261	1262	0
O	1262	1263	.
O	1263	1266	001
O	1266	1267	)
O	1268	1271	but
B-outcome	1272	1282	depression
O	1283	1286	was
O	1287	1297	unaffected
O	1298	1299	(
O	1299	1300	p
O	1301	1302	=
O	1303	1304	0
O	1304	1305	.
O	1305	1308	610
O	1308	1309	)
O	1309	1310	.

O	1311	1315	This
O	1316	1327	prospective
O	1328	1338	randomised
O	1339	1344	trial
O	1345	1347	of
O	1348	1355	support
O	1356	1361	group
O	1362	1374	intervention
O	1375	1377	in
O	1378	1379	a
O	1380	1385	large
O	1386	1396	homogenous
O	1397	1402	group
O	1403	1405	of
O	1406	1412	breast
O	1413	1419	cancer
O	1420	1425	women
O	1426	1432	showed
O	1433	1434	a
O	1435	1448	statistically
O	1449	1460	significant
O	1461	1467	effect
O	1468	1470	on
O	1471	1479	lowering
O	1480	1487	anxiety
O	1488	1492	over
O	1493	1497	time
O	1497	1498	.

O	1499	1501	No
O	1502	1515	statistically
O	1516	1527	significant
O	1528	1534	effect
O	1535	1537	of
O	1538	1550	intervention
O	1551	1556	could
O	1557	1559	be
O	1560	1564	seen
O	1565	1567	on
O	1568	1578	depression
O	1578	1579	.
